Trial Profile
Trazenta Randomized study for USing insulin patient of Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2021
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms TRUST2
- 28 Jan 2021 Primary endpoint, Assessment of efficacy to glycemic control from baseline (Visit 0) to 16 weeks. Quantity change of HbA1c, has been met as per results published in the Advances in Therapy.
- 28 Jan 2021 Results published in the Advances in Therapy
- 04 Mar 2019 Status changed from active, no longer recruiting to completed.